Dublin, Jan. 15, 2019 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies" report has been added to ResearchAndMarkets.com's offering.
The Southeast Asia AD market will be valued at $848.6m in 2024, growing from $423.2m in2017, at a compound annual growth rate of 10.5%. The increase in uptake of recently approved and emerging targeted therapeutics, along with the continued uptake of existing branded therapies, will also propel market growth. Dupixent has the potential to be a game-changing therapy, as it is a first-in-class IL-drug and the first biologic approved for the treatment of Atopic Dermatitis (AD). In addition, Dupixent's expected launch in Singapore and Taiwan will be the most important event in the Atopic Dermatitis (AD) market space in the near-term. The continued uptake of this novel targeted therapy will contribute to the increasing ACoT and in turn drive the market in South Korea, Singapore and Taiwan. In recent years, targeted therapies have become a focus for Atopic Dermatitis (AD) treatment research. Biologics, small molecule and other therapies targeting specific immune pathways for Atopic Dermatitis (AD) are currently being studied in various phases along the drug development pipeline. The late-stage pipeline contains promising therapies that have the potential to achieve approval and launch over the forecast period. On the other hand, novel topical therapies are still needed in the Atopic Dermatitis (AD) disease space, as current topical options are limited to corticosteroids and calcineurin inhibitors, which are associated with side effects, a long treatment duration, and low compliance. The launch of new pipeline therapies with better clinical profiles will significantly increase the treatment options for Atopic Dermatitis (AD) patients and improve care levels. Due to the positive impact expected to be made by therapies over the forecast period, the Atopic Dermatitis (AD) market is anticipated to undergo expansion in South East Asia. Scope
- What are the key factors driving the Southeast Asia AD treatment market?
- What classes of drugs dominate the market?
- How will the market respond to recent approval?
- How will novel IL-4Ra inhibitor therapy Dupixent, which holds first-to-market advantage, contribute to growth?
- The AD pipeline contains a range of molecule types and molecular targets, including those that are well established in AD and novel target therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- What are the common targets and mechanisms of action of pipeline therapies?
- Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- What are the commercial prospects for the most promising late-stage products?
- How will the approval of tralokinumab, furestem-AD, baricitinib, PAC-14028 and PF-04965842, affect the competitive landscape?
- Various drivers and barriers will influence the market over the forecast period.
- Which factors are most likely to drive the market in these countries?
- What licensing and co-development deals have occurred within this therapy area since 2007?
Key Topics Covered:
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Disease Introduction 2.2 Epidemiology 2.3 Symptoms 2.4 Etiology and Pathophysiology 2.4.1 Etiology 2.4.2 Pathophysiology 2.5 Diagnosis 2.5.1 Hanifin and Rajka Diagnostic Criteria 2.5.2 UK Working Party's Diagnostic Criteria 2.5.3 Biomarkers 2.6 Classification and Disease Stages 2.7 Prognosis 2.8 Treatment Options and Guidelines 2.8.1 Emollients 2.8.2 Topical corticosteroids 2.8.3 Topical calcineurin inhibitors 2.8.4 Antimicrobials 2.8.5 Systemic immunosuppressive therapy 2.8.6 Biologics 2.8.7 Other treatments 2.8.8 Wet wrap therapy 2.9 Treatment guidelines 3 Marketed Products 3.1 Overview 3.1.1 Dupixent (dupilumab) - Regeneron and Sanofi 3.1.2 Protopic (tacrolimus) - Astellas 3.1.3 Elidel (Pimecrolimus) - Novartis 3.1.4 Cyclosporine 3.1.5 Xolair (omalizumab) - Novartis and Genentech (Off-Label Therapy) 3.1.6 Eucrisa (crisaborole) - Pfizer 3.1.7 Other Therapeutic Drug Classes Used in Atopic Dermatitis 3.2 Comparative Efficacy and Safety of Marketed Products 4 Pipeline Analysis 4.1 Overview 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 4.3 Pipeline by Molecular Target 4.4 Promising Pipeline Candidates 4.4.1 Tralokinumab - LEO Pharma 4.4.2 Furestem-AD - Kang Stem Biotech 4.4.3 Baricitinib - Eli Lilly and Incyte Corporation 4.4.4 PAC-14028- Amorepacific 4.4.5 PF-04965842 - Pfizer 4.5 Comparative Efficacy and Safety of Pipeline Products 4.6 Product Competitiveness Framework 5 Clinical Trial Analysis 5.1 Failure Rate 5.1.1 Overall Failure Rate 5.1.2 Failure Rate by Phase and Molecule Type 5.1.3 Failure Rate by Phase and Molecule Target 5.2 Clinical Trial Size 5.2.1 Patient Enrollment per Trial by Molecule Type and Stage of Development 5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 5.2.3 Patient Enrollment per Product by Molecule Type and Stage of Development 5.2.4 Patient Enrollment per Product by Molecular Target and Stage of Development 5.3 Clinical Trial Duration 5.3.1 Clinical Trial Duration by Molecule Type 5.3.2 Clinical Trial Duration by Molecular Target 5.4 Competitive Clinical Trials Metrics Analysis 6 Multi-scenario Forecast 6.1 Geographical Market 6.2 Southeast Asian Markets 6.3 South Korea 6.3.1 Treatment Usage Patterns 6.3.2 Annual Cost of Therapy 6.3.3 Market Size 6.4 Singapore 6.5 Taiwan 6.6 Malaysia 6.7 Philippines 6.8 Thailand 6.9 Vietnam 6.10 Indonesia 7 Drivers and Barriers 7.1 Drivers 7.1.1 Increasing awareness and diversified healthcare reform to boost market growth 7.1.2 Promising pipeline products that target unmet needs for AD 7.1.3 Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents 7.2 Barriers 7.2.1 First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market 7.2.2 Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products 7.2.3 The complexity of the multiple etiologies that lead to AD means that treatment outcomes with existing drugs are not universal across all patient groups 8 Deals and Strategic Consolidations 8.1 Licensing Deals 8.1.1 Deals by Region and Value 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 8.1.4 Key Licensing Deals 8.2 Co-development Deals 8.2.1 Deals by region, value, year, stage of development, molecule type and molecular target 8.2.2 Key Co-development Deals 9 Appendix 9.1 All Pipeline Drugs by Stage of Development 9.1.1 Discovery 9.1.2 Preclinical 9.1.3 Phase I 9.1.4 Phase II 9.1.5 Phase III 9.2 Summary of Multi-Scenario Market Forecasts to 2024 9.4 Abbreviations 9.5 Research Methodology
Companies Mentioned
- Amorepacific
- Astellas
- Cyclosporine
- Eli Lilly and Incyte Corporation
- Genentech
- Kang Stem Biotech
- LEO Pharma
- Novartis
- Pfizer
- Regeneron
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/research/3...llion?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Immune Disorders Drugs, Dermatological Drugs
